ME Therapeutics Holdings, Inc. (TSE:METX) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
ME Therapeutics Holdings Inc. has announced a strategic partnership with NanoVation Therapeutics to develop mRNA-based cancer therapies targeting myeloid cells, utilizing NanoVation’s advanced lipid nanoparticle technologies. The collaboration will focus on testing the delivery and efficacy of these therapies in a preclinical mouse model, with the potential to fast-track new cancer treatments. This initiative combines ME Therapeutics’ expertise in immuno-oncology with NanoVation Therapeutics’ leading RNA delivery technology.
For further insights into TSE:METX stock, check out TipRanks’ Stock Analysis page.
